<DOC>
	<DOCNO>NCT01759420</DOCNO>
	<brief_summary>The purpose study ass use medication ondansetron ( zofran ) emergency department . There study ability ondansetron cause prolongation QT interval ( certain measurement EKG ) anesthesia cancer patient , emergency department patient . This observational study patient go receive anti-nausea medicine ondansetron emergency department EKG perform every 2 minute 20 minute determine QT interval prolongs return normal time period . Any serious outcome report . There expected adverse outcome routinely use medication .</brief_summary>
	<brief_title>Ondansetron QT Interval In Adult Emergency Department Patients</brief_title>
	<detailed_description>Intravenous ondansetron routinely use adult emergency department patient experience nausea vomiting . The FDA change drug label warn prolongation QT interval require manufacturer perform additional study . There rare case report cardiac electrical toxicity include QT prolongation , atrial fibrillation , severe bradycardia , ventricular tachycardia , supraventricular tachycardia , potential Torsades de Pointes . All report literature ondansetron come post-operative patient , patient receive chemotherapy , healthy volunteer , never assess emergency department population . Adult emergency department patient meet exclusion criterion enrol prior receive intravenous ondansetron . Administration ondansetron discretion attend physician . A twelve-lead electrocardiogram ( EKG ) 12-lead rhythm strip generate prior drug administration , every 2 minute follow drug administration 20 minute administration . During entire 20 minute patient cardiac monitor define adverse cardiac electrical event occur ( non-sinus rhythm , severe bradycardia , sudden cardiac death ) patient treat use standard Advanced Cardiac Life Support method admit continued monitoring . The mean maximal QTc prolongation ( measure Bazett formula ) , well rate adverse cardiac event 95 % confidence interval report . The global objective study determine routine use intravenous ondansetron emergency department associate cardiac risk . The primary objective determine mean maximal prolongation QTc interval baseline measure Bazett formula . The secondary objective determine number severe adverse cardiac electrical event ( non-sinus rhythm , severe bradycardia , sudden cardiac death ) associate routine use intravenous ondansetron adult emergency department patient .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Age &gt; 18 Patient receive 4mg intravenous ondansetron Age &lt; 18 know long QT syndrome receive oral intravenous ondansetron within 4 hour enrollment coadministration know QT prolong agent QTc baseline &gt; 450 m male &gt; 470ms female allergy know hypersensitivity ondansetron alter mental status nonsinus rhythm baseline EKG hypokalemia ( define low limit normal reference laboratory ) hypomagnesemia ( define low limit normal reference laboratory ) presentation chest pain sign ischemia baseline EKG QRS duration &gt; 120 msec bundle branch block ( right left ) ventricular preexcitation sign leave ventricular hypertrophy repolarization abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Ondansetron</keyword>
	<keyword>QT interval</keyword>
	<keyword>QTc</keyword>
	<keyword>QT prolongation</keyword>
	<keyword>Drug induce QT prolongation</keyword>
</DOC>